Pfizer continues to explore new avenues in cancer treatment, including the development of next-generation immunotherapies and combination therapies. The company is also investigating the role of biomarkers in predicting treatment response and resistance. Ongoing clinical trials are aimed at expanding the indications for existing drugs and discovering novel therapeutic targets.
